Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging intravenous esketamine for adolescents with depression and suicidal ideation
ChiCTR2500095496Phase 4Not yet recruiting
- Sponsor
- The Affiliated Brain Hospital of Guangzhou Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (4 arms), sponsored by The Affiliated Brain Hospital of Guangzhou Medical University. Primary endpoints: Columbia-Suicide Severity Rating Scale and Beck Scale for Suicide Ideation. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500095496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095496.